Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely however we are beginning to have limited access to the office from 6th July 2020. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
ACT II trial sees further analysis published
30 June 2020
The CTC-led ACT II trial, a large randomised anal cancer study which took place in the UK between 2001-2008, has this month seen further ad-hoc analysis of its data published in the medical journal Annals of Oncology.

The trial’s predecessor, ACT I, led to chemoradiation becoming the standard of care for patients with anal cancer. ACT II was funded by Cancer Research UK and recruited 940 patients with localised squamous cell carcinoma of the anus (SCCA). The study looked to investigate whether replacing mitomycin with cisplatin in the chemoradiation schedule improves complete response rate, as well as the impact of maintenance chemotherapy using fluorouracil (5FU)/cisplatin after chemoradiation. The results showed that 5FU and mitomycin with 50.4 Gy radiotherapy in 28 fractions should remain standard practice for treatment of SCCA in the UK. 

Since the first paper was published in The Lancet Oncology in 2013, several retrospective reviews have been conducted on the ACT II trial data. This latest review, whose findings can now be read online, looked at correlations between treatment compliance and long-term patient outcomes.

The main findings from the analysis were:
Compliance to chemotherapy and radiotherapy in radical chemoradiotherapy regimens should be considered as a prognostic factor in future studies
Poor compliance to week 5 chemotherapy is associated with inferior progression free survival (PFS) and overall (OS) 
Extending overall treatment time of radical chemoradiotherapy (50.4 Gy total radiotherapy dose) in anal cancer is associated with poorer outcomes (PFS and OS)
Careful patient selection and close monitoring during treatment is advised to maintain treatment compliance, especially renal function and adverse event/toxicity monitoring  

The full analysis can be found at the Annals of Oncology website.


Links:
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2020 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us